Technology areas: Semiconductors, Circuits & Optics • Medical Devices & Mechanical Engineering
6 pending office actions • 2 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Brien Holden Vision Institute Limited is managing 6 pending office actions within the Semiconductors, Circuits & Optics technology area. These 6 actions are distributed among 5 distinct examiners, indicating a slight concentration in the workload. DARRYL J COLLINS is the busiest examiner for the portfolio, holding 2 pending office actions. This means that while most examiners handle one case, one examiner is responsible for a larger share of the pending matters.
The 6 pending office actions are situated within 2 distinct art units, which suggests a relatively focused technical scope despite the involvement of 5 examiners. With 6 pending actions and 2 art units, the company may benefit from some consistency in technical review across its applications. However, the need to manage 5 different examiners, including DARRYL J COLLINS who holds 2 pending actions, still requires a varied prosecution strategy.
Practitioners should focus on the 2 pending office actions assigned to DARRYL J COLLINS, as this represents the only point of examiner concentration. The 2 distinct art units provide a relatively narrow technical framework for the 6 pending matters, but the diversity of 5 examiners still demands a case-by-case analysis. This profile indicates a specialized optics portfolio that requires balancing a primary examiner relationship against several individual ones.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLLINS, DARRYL J | 2 | 89.1% | +4.9% |
| PINKNEY, DAWAYNE | 1 | 80.7% | +17.9% |
| TYSON, MELANIE RUANO | 1 | 68.4% | +18.9% |
| BOUTSIKARIS, LEONIDAS | 1 | 85.2% | +16.9% |
| EDENFIELD, KUEI-JEN L | 1 | 78.2% | +14.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021711 | Ophthalmic Devices, Systems and/or Methods for Management of Ocular Conditions and/or Reducing Night Vision Disturbances | BOUTSIKARIS, LEONIDAS | 8d |
| 18990561 | Lenses, Devices, Methods and Systems for Refractive Error | COLLINS, DARRYL J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18994429 | Ophthalmic Devices, Systems and/or Methods for Management of Ocular Conditions | COLLINS, DARRYL J | — |
| 18767365 | Devices, Systems and/or Methods for Myopia Control | PINKNEY, DAWAYNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17236657 | Ophthalmic Lenses for Reducing, Minimizing, and/or Eliminating Interference on In-Focus Images by Out-of-Focus Light | EDENFIELD, KUEI-JEN L | 208d overdue |
| 18280882 | Intraocular Lenses for Reducing Peripheral Pseudophakic Dysphotopsia | TYSON, MELANIE RUANO | 4d overdue |
| 18021711 | Ophthalmic Devices, Systems and/or Methods for Management of Ocular Conditions and/or Reducing Night Vision Disturbances | BOUTSIKARIS, LEONIDAS | 8d |
| 18767365 | Devices, Systems and/or Methods for Myopia Control | PINKNEY, DAWAYNE | — |
| Art Unit | Apps |
|---|---|
| 2872 | 2 |
| 3774 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18994429 | Ophthalmic Devices, Systems and/or Methods for Management of Ocular Conditions | COLLINS, DARRYL J | — | §102§112Other | Non-Final OA | — | Pending | Jan 14, 2025 |
| 18990561 | Lenses, Devices, Methods and Systems for Refractive Error | COLLINS, DARRYL J | — | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18767365 | Devices, Systems and/or Methods for Myopia Control | PINKNEY, DAWAYNE | — | §102§103Other | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18280882 | Intraocular Lenses for Reducing Peripheral Pseudophakic Dysphotopsia | TYSON, MELANIE RUANO | 3774 | §103 | Final Rejection | 4d overdue | Pending | Sep 07, 2023 |
| 18021711 | Ophthalmic Devices, Systems and/or Methods for Management of Ocular Conditions and/or Reducing Night Vision Disturbances | BOUTSIKARIS, LEONIDAS | 2872 | §103 | Non-Final OA | 8d | Pending | Feb 16, 2023 |
| 17236657 | Ophthalmic Lenses for Reducing, Minimizing, and/or Eliminating Interference on In-Focus Images by Out-of-Focus Light | EDENFIELD, KUEI-JEN L | 2872 | §103 | Final Rejection | 208d overdue | Pending | Apr 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial